Antioxidants block prostate cancer in Lady transgenic mice

Cancer Research

Volumn 64, Issue 16, 2004, Pages 5891-5896

  Venkateswaran, Vasundara ^a   Fleshner, Neil E ^b   Sugar, Linda M ^a   Klotz, Laurence H ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CYCLINE; LYCOPENE; PROTEIN P27; SELENIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET SUPPLEMENTATION; DISEASE MARKER; DRUG TOLERABILITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIPID DIET; MALE; METASTASIS; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; TOXICITY; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, VIRAL, TUMOR; ANTIOXIDANTS; CAROTENOIDS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DIET; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATIC NEOPLASMS; SELENIUM; TESTOSTERONE; TUMOR SUPPRESSOR PROTEINS; VITAMIN E;

EID: 4143058248     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0690     Document Type: Article

References (49)

1. National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report [review]. Obes Res (Suppl 2):51S-209S, 1998. Erratum in: Obes Res 1998 Nov;6:464.
2. National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report [review]. Obes Res (Suppl 2):51S-209S, 1998. Erratum in: Obes Res 1998 Nov;6:464.
3. Fleshner NE, Bagnell PS, Klotz LH, Venkateswaran V. Dietary fat and prostate cancer. J Urol 2004;171:SI9-24.
4. Zock PL. Dietary fats and cancer. Curr Opin Lipidol 2001;12:5-10.
5. Fleshner NE, Kucuk O. Antioxidant dietary supplements: Rationale and current status as chemopreventive agents for prostate cancer. Urology 2001;57:90-4.
6. Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomark Prev 2000;9:1171-82.
7. Kucuk O, Sarkar FH, Sakr W, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarker Prev 2001;10:861-8.
8. Gysin R, Azzi A, Visarius T. Gamma-tocopherol inhibits human cancer cell cycle progression and cell proliferation by down-regulation of cyclins. FASEB J 2002;16:1952-4, Epub 2002 Oct 04.
9. Venkateswaran V, Klotz LH, Fleshner NE. Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res 2002;62:2540-5.
10. Venkateswaran V, Fleshner NE, Klotz LH. Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J Urol 2002;168:1578-82.
11. Fleshner N, Fair WR, Huryk R, Heston WD. Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol 1999;161:1651-4.
12. Patterson RE, White E, Kristal AR, Neuhouser ML, Potter JD. Vitamin supplements and cancer risk: the epidemiologic evidence. Cancer Causes Control 1997;8:786-802.
13. Wang Y, Ichiba M, Oishi H, Iyadomi M, Shono N, Tomokuni K. Relationship between plasma concentrations of beta-carotene and alpha-tocopherol and life-style factors and levels of DNA adducts in lymphocytes. Nutr Cancer 1997;27:69-73.
14. Albanes D, Heinonen OP, Huttunen JK, et al. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the alpha-tocopherol beta-carotene cancer prevention study. Am J Clin Nutr 1995;62(6 Suppl):1427S-30S.
15. Rautalahti MT, Virtamo JR, Taylor PR, et al. The effects of supplementation with alpha-tocopherol and beta-carotene on the incidence and mortality of carcinoma of the pancreas in a randomized, controlled trial. Cancer (Phila) 1999;86:37-42.
16. Woodson K, Tangrea JA, Barrett MJ, Virtamo J, Taylor PR, Albanes D. Serum alpha-tocopherol and subsequent risk of lung cancer among male smokers. J Natl Cancer Inst (Bethesda) 1999;91:1738-43.
17. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. J Am Med Assoc 1996;276:1957-63.
18. Clark LC, Dalkin B, Krongrad A, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998;81:730-4.
19. Conn PF, Schalch W, Truscott TG. The singlet oxygen and carotenoid interaction. J Photochem Photobiol B 11:41-7, 1991. Erratum in: J Photochem Photobiol B 1993;17:89.
20. Conn PF, Schalch W, Truscott TG. The singlet oxygen and carotenoid interaction. J Photochem Photobiol B 11:41-7, 1991. Erratum in: J Photochem Photobiol B 1993;17:89.
21. Di Mascio P, Kaiser S, Sies H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys 1989;274:532-8.
22. Rao AV, Fleshner NE, Agarwal S. Serum and tissue lycopene and biomarkers of oxidation in prostate cancer patients: a case-control study. Nutr Cancer 1999;33:159-164.
23. Horvath PM, Ip C. Synergistic effect of vitamin E and selenium in the chemoprevention of mammary carcinogenesis in rats. Cancer Res 1983;43:5335-41.
24. Ip C, White G. Mammary cancer chemoprevention by inorganic and organic selenium: single agent treatment or in combination with vitamin E and their effects on in vitro immune functions. Carcinogenesis (Lond) 1987;8:1763-6.
25. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
26. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
27. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.
28. Thomas GV, Szigeti K, Murphy M, Draetta G, Pagano M, Loda M. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol 1998;153:681-7.
29. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57:3381-5.
30. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998;58:542-8.
31. Greenberg NM, Demayo FJ, Finegold M, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-43.
32. Masumori N, Thomas TZ, Chaurand P, et al. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 2001;61:2239-49.
33. Cai X, Haleem R, Oram S, et al. High fat diet increases the weight of rat ventral prostate. Prostate 2001;49:1-8.
34. Carroll KK, Khor HT. Dietary fat in relation to tumorigenesis. Prog Biochem Pharmacol 1975;10:308-53.
35. Ross RK, Shimizu H, Paganini-Hill A, Honda G, Henderson BE. Case-control studies of prostate cancer in blacks and whites in southern California. J Natl Cancer Inst (Bethesda) 1987;78:869-74.
36. Kolonel LN. Nutrition and prostate cancer. Cancer Causes Control 1996;7:83-4.
37. Whittemore AS, Kolonel LN, Wu AH, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst (Bethesda) 1995;87:652-61.
38. Giovannucci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst (Bethesda) 1993;85:1571-9.
39. Thompson TA, Wilding G. Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells. Mol Cancer Ther 2003;2:797-803.
40. Bhamre S, Whitin JC, Cohen HJ. Selenomethionine does not affect PSA secretion independent of its effect on LNCaP cell growth. Prostate 2003;54:315-21.
41. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst (Bethesda) 1998;90:440-6.
42. McCormick DL, Rao KV. Chemoprevention of hormone-dependent prostate cancer in the Wistar-Unilever rat. Eur Urol 1999;35:464-7.
43. Nakamura A, Shirai T, Takahashi S, Ogawa K, Hirose M, Ito N. Lack of modification by naturally occurring antioxidants of 3,2′-dimethyl-4- aminobiphenyl-initiated rat prostate carcinogenesis. Cancer Lett 1991;58:241-6.
44. Venkateswaran V, Fleshner NE, Klotz LH. Synergistic effect of vitamin E and selenium in human prostate cancer cell lines. Prostate Cancer Prostatic Dis 2004;7:54-6.
45. Prosperi E. Multiple roles of the proliferating cell nuclear antigen: DNA replication, repair and cell cycle control. Prog Cell Cycle Res 1997;3:193-210.
46. Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998;159:941-5.
47. Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular- proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004;64:830-5.
48. Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schroder FH, van der Kwast TH. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein cD44s in surgically treated patients with prostate cancer. J Urol 2000;164:2156-61.
49. Halvorsen OJ, Haukaas SA, Akslen LA, Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 2003;9:1474-9.